Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.81 |
| ▸ | SRD5A1 | P18405 | 7/20 | 0.72 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.72 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.72 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917931 | 0.90 | AR (1.00) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL7080151 | 0.90 | AR (1.00) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL5241935 | 0.90 | AR (1.00) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL5251876 | 0.88 | AR (0.74) | ARSRD5A1SRD5A2LMNA | |
| SCHEMBL5211698 | 0.88 | AR (0.74) | ARSRD5A1SRD5A2LMNA | |
| SCHEMBL5215261 | 0.88 | AR (0.81) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL5214570 | 0.88 | AR (0.81) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL13394306 | 0.87 | AR (0.62) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL5214019 | 0.87 | AR (0.80) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL5211545 | 0.87 | AR (0.80) | ARSRD5A1SRD5A2LMNAABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371367-A1 | Method of treating men with testosterone supplement and 5alpha reductase inhibitor | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-10-05 | — | — | EP | claimed |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2011-06-09 | — | — | US | claimed |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | MEEHAN ALAN | 2011-04-21 | — | — | US | claimed |
| EP-2305352-A1 | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders | Merck Sharp & Dohme Corp. (US) | 2011-04-06 | — | — | EP | claimed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | claimed |
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | claimed |
| EP-1865955-A4 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | claimed |
| EP-1865955-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | Merck & Co., Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006104762-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 2006-10-05 | — | — | WO | claimed |
| EP-0859761-A4 | 4-AZASTEROIDS FOR TREATMENT OF HYPERANDROGENIC CONDITIONS | MERCK & CO INC (US) | 2000-01-26 | — | — | EP | claimed |
| EP-0859761-A1 | 4-AZASTEROIDS FOR TREATMENT OF HYPERANDROGENIC CONDITIONS | Merck & Co., Inc. (US) | 1998-08-26 | — | — | EP | claimed |
| WO-1997010217-A1 | 4-AZASTEROIDS FOR TREATMENT OF HYPERANDROGENIC CONDITIONS | MERCK & CO., INC. (US) | 1997-03-20 | — | — | WO | claimed |
| EP-2371367-A1 | Method of treating men with testosterone supplement and 5alpha reductase inhibitor | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | MEEHAN ALAN | 2011-04-21 | — | — | US | disclosed |
| EP-0859761-A4 | 4-AZASTEROIDS FOR TREATMENT OF HYPERANDROGENIC CONDITIONS | MERCK & CO INC (US) | 2000-01-26 | — | — | EP | disclosed |
| US-6001844-A | 4-Azasteroids for treatment of hyperandrogenic conditions | MERCK & CO., INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0859761-A1 | 4-AZASTEROIDS FOR TREATMENT OF HYPERANDROGENIC CONDITIONS | Merck & Co., Inc. (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997010217-A1 | 4-AZASTEROIDS FOR TREATMENT OF HYPERANDROGENIC CONDITIONS | MERCK & CO., INC. (US) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | ADRA1D, ADRB1, AGER | AR 22/4885SRD5A1 17/4885SRD5A2 26/4885 |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | ADRA1D, ADRB1, AGER | AR 22/4885SRD5A1 17/4885SRD5A2 26/4885 |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | CYP17A1, SHBG, CYP21A2 | AR 12/4885SRD5A1 10/4885SRD5A2 4/4885 |
| US-20110092470-A1 | METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION | ADRA1D, ADRB1, AGER | AR 34/4885SRD5A1 37/4885SRD5A2 53/4885 |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | CYP17A1, SHBG, CYP21A2 | AR 12/4885SRD5A1 10/4885SRD5A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.